Dean F Bajorin

List of Publications by Year
in descending order

118 papers	20,329 citations	50170 46 h-index	20900 115 g-index
123 all docs	123 docs citations	123 times ranked	19472 citing authors

#	Article	IF	Citations
1	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	6.3	3,077
2	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
3	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	13.9	2,677
4	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	6.3	1,728
5	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 1483-1492.	5.1	1,034
6	Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy. Journal of Clinical Oncology, 1999, 17, 3173-3181.	0.8	658
7	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2002, 167, 1295-1298.	0.2	544
8	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	7.7	506
9	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine, 2021, 384, 2102-2114.	13.9	427
10	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
11	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
12	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
13	Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 1995, 76, 824-832.	2.0	265
14	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	0.9	263
15	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Medicine, 2017, 14, e1002309.	3.9	256
16	A role for neoadjuvant gemcitabine plus cisplatin in muscleâ€invasive urothelial carcinoma of the bladder. Cancer, 2008, 113, 2471-2477.	2.0	239
17	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	3.2	225
18	Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis. Cancer, 1993, 72, 3091-3098.	2.0	222

#	Article	IF	Citations
19	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	0.9	202
20	Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. Journal of Clinical Oncology, 2000, 18, 1173-1180.	0.8	187
21	Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. Journal of Clinical Oncology, 2015, 33, 3177-3185.	0.8	187
22	Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2010, 28, 1373-1379.	0.8	170
23	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	3.2	164
24	Surgery for a Post-Chemotherapy Residual Mass in Seminoma. Journal of Urology, 1997, 157, 860-862.	0.2	157
25	Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma. Journal of Clinical Oncology, 1999, 17, 2546-2546.	0.8	152
26	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	9.4	143
27	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer, 1990, 66, 2476-2481.	2.0	119
28	Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	7.7	114
29	Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Cancer, 2000, 88, 1671-1678.	2.0	112
30	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	0.8	110
31	Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer, 1994, 74, 1329-1334.	2.0	105
32	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	3.2	104
33	Genomic Differences Between â€œPrimaryâ€•and â€œSecondaryâ€•Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	0.9	104
34	Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. Journal of Clinical Oncology, 2001, 19, 682-688.	0.8	99
35	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 2014, 50, 3145-3152.	1.3	99
36	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	0.8	97

#	Article	IF	Citations
37	Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2013, 31, 724-730.	0.8	91
38	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell Reports, 2018, 23, 512-521.	2.9	90
39	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	3.2	85
40	Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer, 1994, 73, 2520-2526.	2.0	70
41	Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop. Urology, 2014, 83, 262-265.	0.5	67
42	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. European Urology Oncology, 2020, 3, 728-738.	2.6	61
43	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. American Journal of Surgical Pathology, 2019, 43, 920-927.	2.1	59
44	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Journal of Urology, 2016, 195, 277-282.	0.2	54
45	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
46	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	2.0	50
47	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. Journal of Urology, 2014, 192, 415-419.	0.2	49
48	Methotrexate, Vinblastine, Doxorubicin and Cisplatin Chemotherapy and Cystectomy for Unresectable Bladder Cancer. Journal of Urology, 1996, 156, 368-371.	0.2	47
49	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 637-644.	0.8	46
50	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1312-1322.	0.8	42
51	Two-drug therapy in patients with metastatic germ cell tumors. Cancer, 1991, 67, 28-32.	2.0	41
52	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cellâ€free DNA results. Cancer, 2020, 126, 2597-2606.	2.0	39
53	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. Cancer, 1990, 65, 2465-2470.	2.0	37
54	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37

#	Article	IF	Citations
55	The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience. Oncologist, 2015, 20, 508-515.	1.9	36
56	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.2	36
57	Decompression of epidural metastases from germ cell tumors with chemotherapy. Journal of Neuro-Oncology, 1990, 8, 275-80.	1.4	32
58	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clinical Genitourinary Cancer, 2020, 18, 387-394.	0.9	32
59	Pembrolizumab (pembro) versus investigatorâ€™s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology, 2021, 39, 4532-4532.	0.8	32
60	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 2478-2483.	0.8	31
61	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
62	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	1.6	30
63	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	1.1	27
64	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer, 1993, 72, 3313-3317.	2.0	26
65	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	3.6	26
66	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	0.8	26
67	The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer, 2016, 122, 712-721.	2.0	25
68	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1108-1115.	0.8	24
69	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). Journal of Clinical Oncology, 2023, 41, 43-53.	0.8	24
70	Fundamental immuneâ€“oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179.	13.7	23
71	Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. Cancer, 1991, 67, 1299-1304.	2.0	21
72	First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients. Hematology/Oncology Clinics of North America, 2015, 29, 319-328.	0.9	21

#	Article	IF	Citations
73	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	0.9	21
74	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	3.2	21
75	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. Journal of Urology, 2015, 193, 513-518.	0.2	20
76	Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Investigational New Drugs, 2000, 18, 247-251.	1.2	19
77	Utility of Routine Preoperative ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Journal of Urology, 2020, 204, 254-259.	0.2	19
78	Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4951-E4960.	3.3	17
79	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2019, 37, 2329-2337.	0.8	17
80	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	3.2	15
81	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. PLoS ONE, 2018, 13, e0208422.	1.1	14
82	A phase 2 trial of buparlisib in patients with platinumâ€resistant metastatic urothelial carcinoma. Cancer, 2020, 126, 4532-4544.	2.0	14
83	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports in Oncology, 2021, 14, 430-438.	0.3	14
84	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer, 2021, 124, 1214-1221.	2.9	14
85	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). Bladder Cancer, 2017, 3, 113-119.	0.2	13
86	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. Journal of Urology, 2020, 204, 677-684.	0.2	13
87	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology, 2017, 103, 154-160.	0.5	12
88	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. Urology, 2018, 114, 133-138.	0.5	12
89	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 2020, 38, 1332-1337.	0.8	11
90	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. Journal of Urology, 2017, 197, 391-397.	0.2	10

#	Article	IF	Citations
91	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 248-253.	1.2	10
92	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€urothelial carcinoma of the urinary tract. Cancer Medicine, 2021, 10, 1074-1083.	1.3	10
93	Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, 85, 1145-1150.		9
94	Evaluation of Drug Delivery and Survival Impact of Dose-Intense Relative to Conventional-Dose Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy in Urothelial Cancer. Cancer Investigation, 2000, 18, 626-634.	0.6	9
95	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	1.5	9
96	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU International, 2022, 129, 463-469.	1.3	9
97	Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. Bladder Cancer, 2016, 2, 111-117.	0.2	8
98	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncology, 2019, 5, 1790.	3.4	8
99	Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma. Journal of Urology, 2022, 208, 813-820.	0.2	8
100	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology, 2018, 118, 114-118.	0.5	7
101	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e113-e120.	0.9	7
102	Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. World Journal of Urology, 2019, 37, 2401-2407.	1.2	7
103	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	1.1	7
104	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. Urology, 2019, 124, 174-178.	0.5	6
105	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	1.5	6
106	Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	5
107	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, andÂCarboplatin (TI-TIC) With Autologous StemÂCell Reinfusion for Salvage Treatment ofÂGerm Cell Tumors. Clinical Genitourinary Cancer, 2015, 13, 453-460.	0.9	5
108	Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. Journal of Clinical Oncology, 2016, 34, 186-193.	0.8	5

#	Article	IF	Citations
109	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	3.2	4
110	Reply by the Authors. Urology, 2014, 84, 495-496.	0.5	2
111	Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.. Journal of Clinical Oncology, 2021, 39, 4526-4526.	0.8	2
112	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. Clinical Genitourinary Cancer, 2021, 19, e178-e183.	0.9	2
113	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer, 2021, 7, 1-6.	0.2	2
114	Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. , 1995, 76, 824.		2
115	Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. Journal of Clinical Oncology, 2006, 24, 5479-5481.	0.8	1
116	A New Twist to an Old Tale: Immunotherapy in Nonâ€“muscle-invasive Bladder Cancer. European Urology Oncology, 2018, 1, 199-201.	2.6	0
117	Reply by Authors. Journal of Urology, 2020, 204, 259-259.	0.2	0
118	Reply by Authors. Journal of Urology, 2020, 204, 684-684.	0.2	0